Transcode Therapeutics, Inc. announced on March 2, 2026, that it has entered into a licensing agreement with Unleash Immuno Oncolytics, acquiring a pre-clinical cancer treatment program and will issue 1,136,364 shares of Series C Preferred Stock as part of the deal.